Fagron NV (EBR:FAGR)

Market Cap	1.49B
Revenue (ttm)	918.75M
Net Income (ttm)	85.69M
Shares Out	73.29M
EPS (ttm)	1.17
PE Ratio	17.35
Forward PE	14.60
Dividend	0.35 (1.72%)
Ex-Dividend Date	May 19, 2025

Volume	15,531
Average Volume	63,836
Open	20.25
Previous Close	20.30
Day's Range	20.25 - 20.55
52-Week Range	15.14 - 23.50
Beta	0.26
RSI	42.36
Earnings Date	Feb 12, 2026

About Fagron NV

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointest...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 3,828
• Stock Exchange: Euronext Brussels
• Ticker Symbol: FAGR

Financial Performance

In 2024, Fagron NV's revenue was 871.96 million, an increase of 14.28% compared to the previous year's 762.99 million. Earnings were 80.55 million, an increase of 14.18%.